HTLV infection

Condition
HTLV-I and HTLV-II are closely related RNA retroviruses that are transmitted parenterally and sexually, and typically cause life-long chronic infection.

Individual at risk
Recipient

Guidance at RECRUITMENT for adult volunteer donor and maternal donor (cord blood donation)
PERMANENT DEFERRAL
Notify and counsel donor

Guidance at CT/WORK-UP
PERMANENT DEFERRAL
Notify and counsel donor

Justification for guidance
HTLV-I is associated with a small risk of myelopathy and other inflammatory conditions, but more importantly causes immune suppression with consequent risk of cancer and opportunistic infections.

HTLV-II is less common and has no firmly established disease association, but it would be wise to assume that similar immune effects to HTLV-I could occur.

HTLV-I is efficiently transmitted via blood products, with lookback studies suggesting a transmission rate of 13-75%. With the virus’ predilection for CD4+ T-helper cells, this efficiency may be even greater for haematopoietic stem cell products.

Considering that HSCT recipients already face a high degree of immune suppression and concomitant cancer/infection risk, it would seem reasonable to maintain the current recommendation of permanent exclusion of donors with HTLV-I or HTLV-II.

References


Notes

There may also be legal and/or regulatory issues with the collection, transport and administration of a HTLV-positive product.